Related content

The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder

By  

World Psychiatry, Vol. 1723-8617, Iss. 3, 2015-10 ,pp. : 307-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder

By  

Current Psychiatry Reviews, Vol. 6, Iss. 1, 2010-02 ,pp. : 28-45

Bentham Science Publishers

Access to resources Recommend Favorite

Hopelessness as a Predictor of Non-Response to Fluoxetine in Major Depressive Disorder

By Papakostas George   Petersen Timothy   Homberger Caitlin   Green Cassandra   Smith Juliana   Alpert Jonathan   Fava Maurizio  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 19, Iss. 1, 2007-01 ,pp. : 5-8

Informa Healthcare

Access to resources Recommend Favorite

Major depressive disorder and response to citalopram treatment in women attending menopause clinic

By Belső Nóra   Kiss Kitty   Rihmer Zoltán   Tüzkő Nándor   Tóth Sándor János   Paulin Ferenc  

International Journal of Psychiatry in Clinical Practice, Vol. 7, Iss. 4, 2003-12 ,pp. : 269-272

Ashgate Publishing Ltd

Access to resources Recommend Favorite

EEG biomarkers in major depressive disorder: Discriminative power and prediction of treatment response

By Olbrich Sebastian   Arns Martijn  

International Review of Psychiatry, Vol. 25, Iss. 5, 2013-10 ,pp. : 604-618

Informa Healthcare

Access to resources Recommend Favorite